Can Moderna's Aggressive Cost Cuts Help Turn Things Around for Its Stock?
Moderna (NASDAQ: MRNA) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future.
Moderna norovirus vaccine trial on hold by US FDA over neurological side effect
Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...
Moderna to Present at Upcoming Conferences in March 2025
Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences: ...
Moderna beats on revenue but loses more than expected as it scales down manufacturing
It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...
Moderna Posts Wider-Than-Expected Q4 Loss, 2025 Sales Outlook Disappoints
Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for ...
These Stocks Are Moving the Most Today: Nvidia, Snowflake, Tesla, Moderna, Salesforce, Super Micro, Vistra, and More
Nvidia reports better-than-expected fourth-quarter earnings as revenue jumps 78% on demand for the company’s ...
Moderna, Inc. (MRNA): A Bull Case Theory
We came across a bullish thesis on Moderna, Inc. (MRNA) on wallstreetbets Subreddit Page by YouAlwaysHaveAChoice. In this ...
Zacks.com on MSN3d
Moderna (MRNA) International Revenue Performance Explored
Have you assessed how the international operations of Moderna (MRNA) performed in the quarter ended December 2024? For this biotechnology company, possessing an expansive global footprint, parsing the ...